IL13 and neoplasm: Another type of CAR utilizes the single-domain antibodyfragments from camelid heavy-chain antibodies as the antigen-binding moiety.This offers advantages such as a smaller size and higher stability.Ligand-receptor pairs, such as interleukin-13 (IL-13) mutein-bindingIL-13Rα2⁠,9 APRIL (a proliferation-inducingligand),10,11 or NKG2D(natural killer group 2D),12 recognizing stress ligands can alsobe engineered into CARs, thus allowing the targeting of tumor-associatedantigens without the need for antibodies.